Analytical Data
-
Gene name
PIAS1
- Application
-
Alternative Names
GBP; DDXBP1; GU/RH-II; ZMIZ3; Gu-binding protein; Zinc Finger,MIZ-Type Containing 3; DEAD/H(Asp-Glu-Ala-Asp/His)Box Binding Protein 1; RNA helicase II-binding protein
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75925
-
Expression Region
Glu409~Pro645
-
Molecular Weight
29kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PIAS1 (Protein Inhibitor of Activated STAT1) is an E3 ubiquitin ligase that plays a crucial role in regulating various cellular processes, including immune responses, gene expression, and signal transduction pathways. It modulates the activity of STAT proteins, which are pivotal in mediating cellular responses to cytokines and growth factors. Given its involvement in key regulatory mechanisms, aberrations in PIAS1 function can contribute to various diseases, including autoimmune disorders and cancer. Recent studies have highlighted the significance of PIAS1 in the regulation of the NF-κB and p53 pathways, further emphasizing its potential as a therapeutic target. The recombinant expression of PIAS1 in various systems facilitates the investigation of its structural characteristics and functional dynamics, providing insights into its ligase activity and interaction with substrate proteins. Through the use of recombinant PIAS1, researchers aim to decipher its role in post-translational modifications and elucidate its impact on cellular signaling networks. This research is critical for advancing our understanding of PIAS1’s contributions to cellular dysfunctions and for developing innovative strategies to manipulate its activity for therapeutic benefit.
